21. November 2009 00:12
As a result of successful events organised last year, a second Joint Scientific Forum, organised by the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD), two of the most respected professional medical organisations in Europe, will be held from 27-29 November at three venues across China - Beijing, Shanghai and Guangzhou.
[More]
18. November 2009 10:42
AstraZeneca today announced the results of the phase II studies, ONSET/OFFSET and RESPOND for ticagrelor (BRILINTA(TM)) at the annual American Heart Association (AHA) Scientific Sessions in Orlando, FL,with ONSET/OFFSET study results being simultaneously published in the medical journal Circulation.
[More]
18. November 2009 05:33
In a phase IIb study in 589 patients with primary hypercholesterolemia or mixed hyperlipidemia treated with anacetrapib as monotherapy or co-administered with atorvastatin, there were persistent lipid effects in the higher dose arms in both the monotherapy and co-administration treatment groups eight weeks after stopping active therapy with anacetrapib.
[More]
18. November 2009 05:05
A new analysis of the JUPITER trial, released today at the American Heart Association meeting in Orlando, Florida, demonstrates that CRESTOR (rosuvastatin calcium) 20mg reduced first major cardiovascular events by 46%.
[More]
c902b942-aa3a-42cb-aa84-2bbe56fad227|0|.0
Posted in: Medical Condition News | Women's Health News | Pharmaceutical News
Tags: Angina, Atherosclerosis, Breast Cancer, Calcium, Cancer, Cardiology, Cardiovascular Disease, Cholesterol, Coronary Heart Disease, Diet, Lipoprotein, Neuroscience, Oncology, Rosuvastatin, Smoking, Statin, Stroke
18. November 2009 04:53
Data released today at the American Heart Association (AHA) Scientific Sessions 2009 define the increased risk of heart attacks and cardiovascular disease in patients with low levels of HDL-C (known as "good cholesterol"). The data also determine that statins are unable to significantly impact the heart attack or cardiovascular disease risks associated with low HDL-C.
[More]
17. November 2009 10:42
Genzyme Corp. and Isis Pharmaceuticals Inc. announced that data from the phase 3 study of mipomersen in patients with homozygous familial hypercholesterolemia (hoFH) were presented today at the American Heart Association’s Scientific Sessions.
[More]
1a400a77-bfd0-472a-9ee1-b2297389c9de|0|.0
Posted in: Drug Trial News | Medical Condition News
Tags: Antisense, Atherosclerosis, Biotechnology, Cancer, Carbohydrate, Cardiovascular Disease, Cholesterol, Coronary Heart Disease, Hypercholesterolemia, Kidney Disease, Lipids, Lipoprotein, Metabolism, microRNA, Statin, Transplant
17. November 2009 05:25
Top Institute Pharma has formed a consortium with Actelion Pharmaceuticals Ltd, Erasmus Medical Centre and Maastricht University to define new modalities for the treatment of hypertension (high blood pressure) and associated vascular complications such as heart and kidney failure, myocardial infarction and stroke.
[More]
17. November 2009 04:29
Aterovax SA, a company developing innovative products for atherosclerosis, today announced data demonstrating that its blood test for secretory phospholipase A2 (sPLA2) activity significantly improves cardiovascular risk prediction in patients with stable coronary artery disease (CAD) over a 5 year period, independent of established risk markers, including C-reactive protein.
[More]
66ace4d3-8c30-4f54-aa13-bc14652022b0|0|.0
Posted in: Device / Technology News | Medical Condition News
Tags: Angiotensin, Atherosclerosis, Biomarker, Cardiovascular Disease, Coronary Artery Disease, Coronary Heart Disease, Hospital, Lipoprotein, Pathology, Stenosis, Stroke, Trandolapril
17. November 2009 03:11
Healthy, older adults free of heart disease need not fear that bouts of rapid, irregular heartbeats brought on by vigorous exercise might increase short- or long-term risk of dying or having a heart attack, according to a report by heart experts at Johns Hopkins and the U.S. National Institute on Aging (NIA).
[More]
17. November 2009 01:03
Heart experts at Johns Hopkins are calling premature the early halt of a study by researchers at Walter Reed Army Medical Center and Washington Hospital Center on the benefits of combining extended-release niacin, a B vitamin, with cholesterol-lowering statin medications to prevent blood vessel narrowing. Cardiovascular atherosclerosis, as it is also known, is believed responsible for one in three deaths in the United States each year.
[More]
e8fab304-a654-4ac1-bd36-a5bdf8db6b4c|0|.0
Posted in: Medical Condition News | Pharmaceutical News
Tags: Aspirin, Atherosclerosis, Blood Pressure, Blood Vessel, Cardiology, Cholesterol, Coronary Artery Disease, Coronary Heart Disease, Diet, Hospital, Smoking, Statin, Stroke
16. November 2009 09:14
China Medicine Corporation, a developer and a leading distributor of prescription and over-the-counter pharmaceuticals, traditional Chinese medicines (TCM), nutritional and dietary supplements, and medical devices and medical formulations, today announced its third quarter 2009 results.
[More]
16. November 2009 07:53
Human Genome Sciences, Inc. today announced that it has received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) relating to the Company’s Biologics License Application (BLA) requesting the approval of raxibacumab for use in the treatment of inhalational anthrax. The FDA issues Complete Response Letters to request additional information needed to complete the review of a BLA.
[More]
3188a212-2b6e-433f-a59c-a41d46de3d12|0|.0
Posted in: Disease/Infection News | Pharmaceutical News
Tags: Anthrax, Antibody, Apoptosis, Cancer, Cell, Coronary Heart Disease, Diabetes, Health and Human Services, Hepatitis C, Lupus, Systemic Lupus Erythematosus
16. November 2009 06:38
Patients with coronary heart disease who practiced the stress-reducing Transcendental Meditation® technique had nearly 50 percent lower rates of heart attack, stroke, and death compared to nonmeditating controls, according to the results of a first-ever study presented during the annual meeting of the American Heart Association in Orlando, Fla., on Nov.16, 2009.
[More]
13. November 2009 01:45
NicOx S.A. today announced that a phase 1b, first-in-man study for NCX 6560, versus placebo and Lipitor® (atorvastatin), has met its primary and secondary objectives. The top-line results demonstrated very good safety and tolerability for all the tested doses of NCX 6560, as well as the expected cholesterol lowering profile.
[More]
16a7012b-d78f-446e-9b5b-14867f97637f|0|.0
Posted in: Drug Trial News | Medical Condition News
Tags: Anti-Inflammatory, Atherosclerosis, Atorvastatin, Cholesterol, Coronary Heart Disease, Lipoprotein, New Drug Application, Nitric Oxide, Osteoarthritis, Stroke, Thrombosis
12. November 2009 08:27
A new study from the University of Warwick has discovered taking too much of the essential mineral selenium in your diet can increase your cholesterol by almost 10%.
[More] 
Subscribe